

Supplementary Table 1. National Comprehensive Cancer Network Recommendations for the Selection of Different Treatment Options Based on BCR-ABL Kinase Domain Mutation Status¹²⁷

Mutation	Therapeutic Options								
	Imatinib	High-Dose Imatinib	HSCT	Nilotinib	Dasatinib	Ponatinib	Bosutinib	Omacetaxine	Clinical Trial
T315I			☐			☐		☐	☐
V299L				☐		☐		☐	
T315A	☐			☐		☐	☐	☐	
F317L/V/I/C				☐		☐	☐	☐	
Y253H, E255K/V, F359V/I/C					☐	☐	☐	☐	
Any other mutations		☐		☐	☐	☐	☐	☐	

Abbreviation: HSCT = hematopoietic stem cell transplantation.

- a. Preferred option.
- b. Omacetaxine is an option for patients with resistance or intolerance to ≥ 2 TKIs.
- c. If mutation detected after dasatinib.
- d. There are not sufficient data on dose escalation available to indicate if mutations with lower IC values are sensitive to high dose imatinib.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Chronic Myelogenous Leukemia V.4.2013. © National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines[®] and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK[®], NCCN[®], NCCN GUIDELINES[®], and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

Supplemental Figure 1.

Schematic Map of Some of the Most Common Amino Acid Substitutions Identified From Clinical Specimens in Patients Resistant to Imatinib. The Stars Highlight Regions Involved in Imatinib Binding. Mutations in Italics Have Been Found to be Single Nucleotide Polymorphisms^a

Abbreviations: A loop = activation loop; P loop = phosphate-binding loop; SH2 = SRC homology 2; SH3 = SRC homology 3.

^aReproduced with permission of the American Society of Hematology, from Soverini S, et al. Blood 118(5), 2011: 1208-1215,⁶⁹ permission conveyed through Copyright Clearance Center, Inc.

